Miglitol-d4
(Synonyms: BAY1099-d4; BAY-m1099-d4) 目录号 : GC47675
A neuropeptide with diverse biological activities
Cas No.:2714473-10-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Miglitol-d4 is intended for use as an internal standard for the quantification of miglitol by GC- or LC-MS. Miglitol is an inhibitor of α-glucosidases (IC50s = 0.35, 0.11, 1.3, and 1.2 µM for human lysosomal α-glucosidase and rat sucrase, maltase, and isomaltase, respectively).1 It is selective for human α- over β-glucosidase (IC50 = 84 µM). Miglitol (10 mg/kg) decreases blood glucose levels in sucrose-loaded Goto-Kakizaki (GK) type 2 diabetic rats.2 Dietary administration of miglitol (40 mg/100 g diet) for 8 weeks decreases changes in HbA1c levels compared with control rats fed a normal diet. Formulations containing miglitol have been used in the treatment of type 2 diabetes.
1.Kuriyama, C., Kamiyama, O., Ikeda, K., et al.In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell culturesBioorg. Med. Chem.16(15)7330-7336(2008) 2.Goda, T., Suruga, K., Komori, A., et al.Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki ratsBr. J. Nutr.98(4)702-710(2007)
| Cas No. | 2714473-10-4 | SDF | |
| 别名 | BAY1099-d4; BAY-m1099-d4 | ||
| Canonical SMILES | OC([2H])([2H])C([2H])([2H])N1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO | ||
| 分子式 | C8H13D4NO5 | 分子量 | 211.3 |
| 溶解度 | DMSO: soluble,Water: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.7326 mL | 23.663 mL | 47.3261 mL |
| 5 mM | 0.9465 mL | 4.7326 mL | 9.4652 mL |
| 10 mM | 0.4733 mL | 2.3663 mL | 4.7326 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet